Actinium Pharmaceuticals Announces Oral Presentation at EANM 2026 Highlighting First-in-Human Phase 1 Study of ATNM-400, a Non-PSMA Targeting Radiotherapy, in Prostate Cancer
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
- Wall Street sinks as Nasdaq falls over 2% on AI cost worries
- Meta’s new Class C stock to keep Zuckerberg in California, fund AI spending spree
- Oil hits five-month high as Houthi attacks stoke supply fears
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
| Actinium Pharmaceuticals, Inc. (NYSE: ATNM) | Delayed: 1.59 +0.21 (15.22%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $1.38 | 52 Week High | $3.50 | |||
| Open | $1.33 | 52 Week Low | $0.86 | |||
| Day High | $1.60 | P/E | N/A | |||
| Day Low | $1.33 | EPS | $-7.61 | |||
| Volume | 543,044 | |||||
